Exelixis Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Exelixis Bundle
Unlock Strategic Clarity
Curious where Exelixis’ products land — Stars, Cash Cows, Dogs, or Question Marks? This snapshot teases the shifts in market share and growth potential, but the full BCG Matrix gives the quadrant-by-quadrant clarity you need. Purchase the complete report for detailed placements, data-backed recommendations, and ready-to-use Word and Excel files. It’s the shortcut to strategic decisions that actually move the needle.
Stars
Cabometyx combo uptake in 1L RCC
Cabometyx+nivo shows strong share in the fast-growing 1L RCC checkpoint-combo market, which registered double-digit growth in 2024, and uptake is still climbing. The clinical-value story continues to pull through but requires constant promotion and field muscle to sustain prescribing momentum. If Exelixis holds share while the category expands, this franchise can mature into a powerhouse. Invest to defend positioning and keep guideline momentum warm.
Cabometyx expansion in HCC and other solid tumors
High-growth tumor types like HCC (905,677 new global cases in 2020 per GLOBOCAN) are seeing rising systemic therapy use, and Cabometyx (cabozantinib; FDA approved in HCC 2019) is already embedded in treatment algorithms. New trial data and real-world evidence broaden indications and line placement, but continuous evidence generation is required. Maintain tight access, low friction, and active KOL engagement to convert uptake into sustainable revenue.
US oncology commercial engine
US oncology commercial engine delivers scale, reach, and repeatability across a targeted-IO market serving ~1.9 million new US cancer diagnoses in 2024, creating durable pull-through and co-promotion opportunities. It is not won and done: effective payer choreography and pull-through require sustained budget and field intensity. As the market expands the engine compounds results—maintain sales intensity and keep playbooks nimble.
Checkpoint inhibitor partnerships
Checkpoint-inhibitor combos are the hottest segment—PD-(L)1 therapies generated over $50 billion in 2023—and Cabometyx (cabozantinib) synergizes well with IO (cabozantinib+nivolumab approved in RCC 2021), giving Exelixis a meaningful share; however awareness and clear differentiation versus other VEGF–IO combos remain work. Tight, selective partnerships keep Exelixis on the growth curve; more pivotal data, smarter sequencing trials and fewer access barriers are needed.
- Market: PD-(L)1 >$50B (2023)
- Combo edge: Cabometyx+IO approved (RCC, 2021)
- Strategy: tight partnerships to capture growth
- Needs: more data, sequencing clarity, improved access
Label-driven real-world adoption
Label-driven real-world adoption: strong guideline presence plus positive outcomes data drive rapid uptake of Cabometyx, with double-digit YoY commercial growth reported in recent quarters (2024); ongoing clinical education is required to maintain momentum across lines. Sustain registries and HEOR to keep field armed with fresh effectiveness and cost-effectiveness figures.
- Guideline alignment: drives prescribing
- Real-world growth: double-digit YoY (2024)
- Needs: continuous education, registry maintenance
- HEOR: prioritize updated cost-effectiveness data
Checkpoint-combo leads 1L RCC: double-digit 2024 growth, PD-(L)1 tailwinds
Cabometyx+nivo holds strong share in the fast-growing 1L RCC checkpoint-combo segment with double-digit category growth in 2024 and ongoing uptake. Cabometyx is embedded in HCC algorithms (905,677 new global HCC cases in 2020) and benefits from PD-(L)1 market tailwinds (PD-(L)1 >$50B in 2023). US oncology scale (~1.9M new cancer diagnoses in 2024) supports durable pull-through if access and data generation continue.
| Metric | Figure | Implication |
|---|---|---|
| 1L RCC share | High (2024) | Defend with field spend |
| Category growth | Double-digit (2024) | Upside if share held |
| PD-(L)1 sales | >$50B (2023) | Combo tailwinds |
| HCC incidence | 905,677 (2020) | Large addressable market |
| US new cancers | ~1.9M (2024) | Commercial scale |
What is included in the product
Detailed Word Document
Comprehensive BCG analysis of Exelixis' portfolio, showing Stars, Cash Cows, Question Marks, and Dogs with investment moves.
Customizable Excel Spreadsheet
One-page Exelixis BCG Matrix that spots underperformers and growth bets—clean, export-ready for fast C-level decks.
Cash Cows
Cabometyx in mature RCC lines
Cabometyx in mature RCC lines is an established cash cow with predictable demand and steady prescribing patterns; 2024 net product revenue was about $1.1B, supporting consistent cash flow. Margins have improved as clinical practice cycles into habit, enabling >60% gross margins. Maintain light-touch promotion and smart contracting to preserve revenue while milking the asset without bruising the brand.
Cometriq niche indications (e.g., MTC)
Cometriq targets medullary thyroid cancer, which represents about 1–2% of thyroid cancers, keeping the addressable market small but steady in 2024. Limited promotional need and a durable clinical requirement produce reliable, predictable orders, so prioritize supply continuity and clean access. Let it generate cash while optimizing COGS and avoid heavy reinvestment given constrained growth prospects.
Ex-US royalties and milestones via partners
Ex-US royalties and milestone payments from partners are low-growth, high-yield cash cows for Exelixis, historically funding pipeline spend with minimal maintenance costs; in 2024 these partnered streams continued to contribute materially to cash flow. Focus should remain on contract hygiene and demand planning to preserve steady receipts. Don’t fix what isn’t broken.
Lifecycle management efficiencies
Lifecycle management efficiencies turn Cabometyx into a cash cow: formulary wins and strengthened distribution reduce patient access friction while mature patient-support programs compress costs; by 2024 Cabometyx already had three major approved indications (RCC, HCC, DTC) and global net product sales above 1 billion USD, letting the machine run leaner as indications age.
Tweak, don’t rebuild: incremental label expansions and safety-driven dosing tweaks preserve market share and every basis point of margin funds next-line trials and combos without heavy capital raises.
- formulary wins
- distribution strength
- mature patient support
- 3 indications (RCC, HCC, DTC) by 2024
- >$1B global net product sales (2024)
Long-tail prescriber base
Long-tail prescriber base sustains stable community oncology use for Exelixis, with light ongoing education, predictable reorder patterns and solid reimbursement that keep the field present without heavy promotional spend; 2024 net product revenue was about $1.3B, reflecting dependable cash flow rather than a growth story. This segment requires modest field effort to maintain share and converts routine prescriptions into reliable margins.
- Stable demand
- Light education burden
- Steady reorders
- Solid reimbursement
- Dependable cash, not high growth
High-margin oncology cash cow funds R&D while steady royalties sustain cash flow
Cabometyx is a mature cash cow (2024 net product revenue ~1.1B USD) with >60% gross margins; Cometriq delivers steady niche revenue (medullary thyroid ~1–2% of thyroid cancers); partner royalties/milestones provide low-growth recurring cash. Preserve margins via light promotion, formulary wins, supply continuity and minimal reinvestment while funding pipeline spend.
| Asset | 2024 | Role |
|---|---|---|
| Cabometyx | ~1.1B USD; >60% GM | Primary cash cow |
| Cometriq | Small, steady | Niche cash cow |
| Partner streams | Material recurring | Supportive cash |
Full Transparency, Always
Exelixis BCG Matrix
The file you're previewing here is the exact Exelixis BCG Matrix you'll receive after purchase. No watermarks, no demo placeholders—just a fully formatted, analysis-ready report designed by strategy experts. After buying, the final file is delivered instantly to your inbox, ready to edit, print, or present to investors and your team. No surprises, just plug-and-play clarity.
Dogs
Underperforming legacy discovery projects
Underperforming legacy discovery projects at Exelixis show low probability and low velocity, often mirroring oncology industry success rates of roughly 5% from Phase I to approval, and they tie up people and capital. Turnarounds are costly and rarely pay back given long timelines and sunk R&D. Sunset, spin out, or shelve these assets. Free the oxygen for programs that can actually run.
Non-core tumor bets with thin differentiation
When a program cannot clearly beat standard of care, market share rarely materializes; oncology approval success from phase I to approval sits near 6.2%, underscoring high attrition and the risk of spending millions with little return.
Exelixis should cut bait early on thinly differentiated tumor bets to avoid sunk-cost escalation and redeploy capital and R&D headcount to higher-probability, sharper-edge opportunities.
Stalled combo concepts that failed in mid-stage
If the signal didn’t show in mid-stage, the market won’t magically appear; Phase II success rates hovered near 30% in 2024, so absent efficacy, further promotion won’t create demand. Raising promo or trial spend won’t fix biology and risks throwing good capital after bad; mid-stage programs commonly consume ~$100–200M before decisive readouts. Close it cleanly and avoid the sunk-cost trap by reallocating resources to higher-probability assets.
Geographies with persistent access drag
Geographies with persistent access drag show low single-digit share and slow uptake; 2024 reimbursement approval rates often remain below 50% in several EM markets, so cash gets stuck behind policy headwinds.
Even heavy investment historically fails to bend the curve within a 3–5 year horizon; maintain minimal presence or plan exit where ROIC remains negative.
Concentrate resources on markets delivering the commercial flywheel—typically core US/EU territories where >80% of Exelixis revenues are realized.
- Tag: low-share
- Tag: slow-uptake
- Tag: policy-headwinds
- Tag: preserve-cash-or-exit
- Tag: focus-on-core-markets
Overlapping internal tools and platforms
Overlapping internal tools drive duplicative spend that rarely changes outcomes; industry studies show 20–30% of software budgets are redundant, slowing R&D and commercial time-to-market. Complexity taxes speed and budget, often adding 10–15% overhead to project timelines. Consolidate or retire platforms to achieve a simpler stack and 15–25% better ROI within 12–24 months.
- Duplicative spend ~20–30%
- Complexity overhead ~10–15%
- ROI gain post-consolidation ~15–25%
Cut low-share oncology assets; consolidate tools to reclaim 15–25% ROI
Exelixis dogs (low-share, slow-uptake assets) tie up talent and cash with ~6.2% Phase I→approval oncology success and ~30% Phase II success (2024), often yielding negative ROIC; cut, spin out, or shelve to redeploy resources. Consolidate duplicate tools (20–30% waste) to recover 15–25% ROI within 12–24 months; prioritize core US/EU markets where >80% revenue sits.
| Metric | Value |
|---|---|
| Phase I→Approval | ~6.2% |
| Phase II Success (2024) | ~30% |
| Dup. Spend | 20–30% |
| ROI Gain Post‑Consol. | 15–25% |
Question Marks
Zanzalintinib (XL092) program
Zanzalintinib (XL092) is a high-potential next-gen TKI in Phase 1/2 as of 2024 with 0% commercial share until pivotal data convert; development will consume cash (clinical programs commonly cost >$200M). If early pivotal signals are tight, press hard and fast to seize growth tumor markets; if signals falter, pivot early to limit burn and reallocate capital.
XB002 (tissue factor ADC)
XB002 sits as a Question Mark in Exelixis’ BCG matrix: the ADC space was valued at about $9.3B in 2024 with ~22% CAGR to 2030 and 12 FDA-approved ADCs by 2024, so upside is real but crowded and execution-heavy. Early clinical signals and patient-selection/combination strategies could catapult it to a Star, or stall development. Allocate targeted R&D spend to define biomarkers and combos. Maintain a kill-switch if differentiation fails to appear.
XL102 (CDK7) in solid tumors
XL102 (CDK7) presents attractive biology with transcriptional addiction rationale in solid tumors but sits in an uncertain competitive lane given multiple CDK and transcriptional inhibitors in development. Success will require crisp biomarker-driven patient selection and well-justified combination strategies to hit meaningful response rates. Fund through tight go/no-go gates and scale only if a clear efficacy bar is met in randomized or robust single-arm readouts.
XL309 (SHP2) and pathway modulators
XL309 (SHP2) sits in a hot target class with tricky tolerability and combo dynamics; peer SHP2 programs such as TNO-155 and RMC-4630 remained in phase 1/2 in 2024, underscoring an unsettled competitive landscape and clear market growth potential. Stage-gate spend, pursue biomarker-led cohorts, and prioritize precision wins—otherwise de-prioritize.
- therapy area: SHP2/RAS pathway
- status: no approved SHP2s in 2024
- competitors: TNO-155, RMC-4630 in phase 1/2
- strategy: biomarker-led cohorts, stage-gate investment
Next-wave IO + targeted combos
Next-wave IO + targeted combos are question marks: growing category demands a differentiated partner but commercial share starts at zero; historically only ~12% of oncology combo programs reach approval, so data, payer/access, and KOL conviction will make or break uptake in 2024. Concentrate on regimens showing clear survival or response-rate edge; go big on winners and prune remainder.
- Prioritize 2–3 regimens with demonstrable OS/PFS benefit
- Invest in phase III-grade biomarker, access, and KOL programs
- Allocate capital skewed: 80/20 to winners vs exploration
Four question-mark oncology assets: 0% share, >$200M burn - enforce tight go/no-go gates
Zanzalintinib, XB002, XL102 and XL309 are Question Marks: high upside but 0% commercial share and development burn >$200M; tight go/no-go gates required.
ADC market $9.3B in 2024, 22% CAGR to 2030, 12 FDA ADCs; IO+targeted combos approval ~12%—prioritize 2–3 regimens and 80/20 capital split.
| Asset | 2024 status | metric | strategy |
|---|---|---|---|
| XB002 | pre/early clinic | ADC market $9.3B | biomarkers/kill-switch |
| XL102 | early | competed CDKs | biomarker-driven |
| XL309 | phase1/2 | no SHP2 approvals | stage-gate cohorts |